SCYX
SCYX clinical trials: SCYNEXIS INC
Every trial on ClinicalTrials.gov where SCYNEXIS INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 18
- Trials linked
- 18
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
SCYX on the catalyst calendar · SCYX registry changes
- Primary completion Nov 7, 2025ActualPhase 3NCT05178862A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral...Scynexis, Inc. · Candidiasis, InvasiveTerminatedSCYXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 1, 2023ActualPhase 1NCT06954493Pharmacokinetic Study in Healthy Lactating Women Exposed to IbrexafungerpScynexis, Inc. · Vulvovaginal CandidiasisCompletedSCYXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 25, 2023ActualPhase 3NCT03059992Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of...Scynexis, Inc. · Invasive CandidiasisCompletedSCYXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 27, 2023ActualPhase 2NCT03672292Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary AspergillosisScynexis, Inc. · Invasive Pulmonary AspergillosisTerminatedSCYXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 16, 2023ActualPhase 3NCT05399641Ibrexafungerp for the Treatment of Complicated Vulvovaginal CandidiasisScynexis, Inc. · Vulvovaginal CandidiasisCompletedSCYXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 14, 2023ActualPhase 3NCT03363841Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida...Scynexis, Inc. · Candidiasis, InvasiveCompletedSCYXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2016ActualPhase 2NCT02244606Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive CandidiasisScynexis, Inc. · MycosesCompletedSCYXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 28, 2023ActualPhase 1NCT05668429ADME Study of [14^C]-Ibrexafungerp in Healthy Male SubjectsScynexis, Inc. · Fungal DiseaseCompletedSCYXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 1, 2021ActualPhase 3NCT04029116Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)Scynexis, Inc. · Recurrent Vulvovaginal CandidiasisCompletedSCYXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 29, 2020ActualPhase 3NCT03987620Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal CandidiasisScynexis, Inc. · Candida VulvovaginitisCompletedSCYXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 21, 2019ActualPhase 3NCT03734991Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)Scynexis, Inc. · Candida VulvovaginitisCompletedSCYXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 4, 2018ActualPhase 2NCT03253094Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal CandidiasisScynexis, Inc. · Candida VulvovaginitisCompletedSCYXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 20, 2019ActualPhase 1NCT04092751Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy SubjectsScynexis, Inc. · PharmacokineticsCompletedSCYXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 3, 2020ActualPhase 1NCT04092725Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy SubjectsScynexis, Inc. · PharmacokineticsCompletedSCYXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 29, 2020ActualPhase 1NCT04307082ADME Study of [14C]-Ibrexafungerp in Healthy Male SubjectsScynexis, Inc. · Fungal InfectionCompletedSCYXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 5, 2016ActualPhase 2NCT02679456Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal CandidiasisScynexis, Inc. · Vulvovaginal CandidiasisCompletedSCYXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2011ActualPhase 2NCT01265511Study of SCY-635, Pegasys and Copegus in Hepatitis CScynexis, Inc. · Hepatitis C InfectionCompletedSCYXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2008ActualPhase 1NCT01290965Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C PatientsScynexis, Inc. · Chronic Hepatitis CCompletedSCYXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 18 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner